Overexpression of integrin a2 promotes osteogenic differentiation of hBMSCs from senile osteoporosis through the ERK pathway

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 5, 2013, Pages 841-852

  Hu, Hui Min ^a   Yang, Liu ^a   Wang, Zhe ^a   Liu, Yan Wu ^a   Fan, Jin Zhu ^a   Fan, Jing ^a   Liu, Jian ^a   Luo, Zhuo Jing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

ERK pathway; human bone marrow stromal cells; integrin; Osteoporosis

Indexed keywords

ALPHA2 INTEGRIN;

AGED; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; HUMAN; MALE; MESENCHYMAL STROMA CELL; METABOLISM; OSTEOBLAST; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; INTEGRIN ALPHA2; MALE; MAP KINASE SIGNALING SYSTEM; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; OSTEOPOROSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84882958112     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Simonen O and Alhava E. [Who is responsible for prevention, diagnosis and treatment of osteoporosis in Finland]. Duodecim 1996; 112: 2173-2176.
2. Old JL and Calvert M. Vertebral compression fractures in the elderly. Am Fam Physician 2004; 69: 111-116.
3. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115: 3318-3325.
4. Mauck KF and Clarke BL. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc 2006; 81: 662-672.
5. Boyle WJ, Simonet WS and Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342.
6. Karsenty G. The complexities of skeletal biology. Nature 2003; 423: 316-318.
7. Raisz LG. Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med 1988; 318: 818-828.
8. Seeman E, Young N, Szmukler G, Tsalamandris C and Hopper JL. Risk factors for osteoporosis. Osteoporos Int 1993; 3 Suppl 1: 40-43.
9. Hollinger JO, Winn S and Bonadio J. Options for tissue engineering to address challenges of the aging skeleton. Tissue Eng 2000; 6: 341- 350.
10. Llorens R. A review of osteoporosis: diagnosis and treatment. Mo Med 2006; 103: 612-615; quiz 615-616.
11. Sweet MG, Sweet JM, Jeremiah MP and Galazka SS. Diagnosis and treatment of osteoporosis. Am Fam Physician 2009; 79: 193-200.
12. Caplan L and Saag KG. Glucocorticoids and the risk of osteoporosis. Expert Opin Drug Saf 2009; 8: 33-47.
13. McNamara LM. Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. J R Soc Interface 2010; 7: 353-372.
14. den Uyl D, Bultink IE and Lems WF. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 2011; 13: 233-240.
15. Parfitt AM. Bone Forming Cells in Clinical Conditions. In: editors. London: B. K. Hall; 1991.
16. Clover J, Dodds RA and Gowen M. Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture. J Cell Sci 1992; 103:267-271
17. Clark EA and Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995; 268: 233-239.
18. Lutolf MP, Gilbert PM and Blau HM. Designing materials to direct stem-cell fate. Nature 2009; 462: 433-441.
19. Grzesik WJ and Robey PG. Bone matrix RGD glycoproteins: immunolocalization and interaction with human primary osteoblastic bone cells in vitro. J Bone Miner Res 1994; 9: 487- 496.
20. Damsky CH. Extracellular matrix-integrin interactions in osteoblast function and tissue remodeling. Bone 1999; 25: 95-96.
21. Franceschi RT. The developmental control of osteoblast-specific gene expression: role of specific transcription factors and the extracellular matrix environment. Crit Rev Oral Biol Med 1999; 10: 40-57.
22. Schneider GB, Zaharias R and Stanford C. Osteoblast integrin adhesion and signaling regulate mineralization. J Dent Res 2001; 80: 1540-1544.
23. Salasznyk RM, Williams WA, Boskey A, Batorsky A and Plopper GE. Adhesion to Vitronectin and Collagen I Promotes Osteogenic Differentiation of Human Mesenchymal Stem Cells. J Biomed Biotechnol 2004; 2004: 24-34.
24. Kundu AK and Putnam AJ. Vitronectin and collagen I differentially regulate osteogenesis in mesenchymal stem cells. Biochem Biophys Res Commun 2006; 347: 347-357.
25. Klees RF, Salasznyk RM, Vandenberg S, Bennett K and Plopper GE. Laminin-5 activates extracellular matrix production and osteogenic gene focusing in human mesenchymal stem cells. Matrix Biol 2007; 26: 106-114.
26. Hughes DE, Salter DM, Dedhar S and Simpson R. Integrin expression in human bone. J Bone Miner Res 1993; 8: 527-533.
27. Moursi AM, Globus RK and Damsky CH. Interactions between integrin receptors and fibronectin are required for calvarial osteoblast differentiation in vitro. J Cell Sci 1997; 110: 2187-2196.
28. Popov C, Radic T, Haasters F, Prall WC, Aszodi A, Gullberg D, Schieker M and Docheva D. Integrins alpha2beta1 and alpha11beta1 regulate the survival of mesenchymal stem cells on collagen I. Cell Death Dis 2011; 2: e186.
29. Sowa H, Kaji H, Yamaguchi T, Sugimoto T and Chihara K. Activations of ERK1/2 and JNK by transforming growth factor beta negatively regulate Smad3-induced alkaline phosphatase activity and mineralization in mouse osteoblastic cells. J Biol Chem 2002; 277: 36024- 36031.
30. Hu Y, Chan E, Wang SX and Li B. Activation of p38 mitogen-activated protein kinase is required for osteoblast differentiation. Endocrinology 2003; 144: 2068-2074.
31. Katz S, Boland R and Santillan G. Modulation of ERK 1/2 and p38 MAPK signaling pathways by ATP in osteoblasts: involvement of mechanical stress-activated calcium influx, PKC and Src activation. Int J Biochem Cell Biol 2006; 38: 2082-2091.